Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline

Dementia with Lewy bodies (DLB) is a progressive dementia frequently accompanied by psychotic symptoms. Similar symptoms can occur in Alzheimer's disease (AD) to a lesser extent. The use of neuroleptic medication to treat psychosis in both diseases is of modest efficacy and can induce severe adverse reactions in DLB. Dopamine D2 receptors in the cerebral cortex are the putative target for the antipsychotic action of these drugs, but the status of these receptors in DLB is unknown. Autoradiography was used to examine the density D2 receptors in postmortem temporal cortex tissue from prospectively assessed patients with neuropathologically confirmed DLB and AD. D2 receptors were substantially (over 40%) and significantly (P < 0.001) reduced in temporal cortex in DLB, and in DLB with concomitant Alzheimer pathology, but was not significantly changed in AD. This reduction correlated with greater cognitive decline (P < 0.01), but was not significantly related to visual or auditory hallucinations or delusions. D2 receptor density was inversely correlated with cortical Lewy body pathology in the neocortex (P < 0.001). The specific loss of D2 receptors associated with Lewy body pathology, in conjunction with our previous finding of low D2 receptors in striatum in DLB, provides a possible explanation for neuroleptic intolerance. That the reduction of D2 receptors correlated with cognitive decline suggests that neuroleptics, as dopamine D2 receptor antagonists, may have a deleterious effect on cognition in DLB. Synapse 61:903–911, 2007. © 2007 Wiley‐Liss, Inc.

[1]  H. Haeske-Dewick Hallucinations in Parkinson's disease: Characteristics and associated clinical features , 1995 .

[2]  Abraham Weizman,et al.  Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. , 1996, Advances in neurology.

[3]  P. Ince,et al.  The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies , 1997, Acta neurologica Scandinavica.

[4]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[5]  G. Zubenko,et al.  Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease , 1991, Biological Psychiatry.

[6]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[7]  I G McKeith,et al.  Report of the second dementia with Lewy body international workshop , 1999, Neurology.

[8]  I G McKeith,et al.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. , 1999, Brain : a journal of neurology.

[9]  P. Thompson,et al.  The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. , 2001, The Journal of clinical psychiatry.

[10]  S. Aalto,et al.  Extrastriatal dopamine D2 receptors in Parkinson's disease: a longitudinal study , 2003, Journal of Neural Transmission.

[11]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[12]  E. Perry,et al.  Visual hallucinations are associated with lower αbungarotoxin binding in dementia with Lewy bodies , 2001, Pharmacology Biochemistry and Behavior.

[13]  W. Hoefnagels,et al.  [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. , 2003, Nederlands tijdschrift voor geneeskunde.

[14]  Robert M. Kessler,et al.  Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride , 1993, Brain Research.

[15]  V Kaasinen,et al.  Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease , 2000, Neurology.

[16]  D. Visvikis,et al.  In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs , 1999, British Journal of Psychiatry.

[17]  K. Marder,et al.  The Columbia University Scale for Psychopathology in Alzheimer's disease. , 1992, Archives of neurology.

[18]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[19]  M. Cookson,et al.  Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: relation to changes in α-synuclein expression , 2002, Neuroscience Letters.

[20]  E. Perry,et al.  Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[21]  L. A. Fetsko,et al.  Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning , 2002, Neuroscience.

[22]  J. Joyce,et al.  Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase‐immunoreactive fibers , 1994, Hippocampus.

[23]  Alan J. Thomas,et al.  A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodies , 2005, International journal of geriatric psychiatry.

[24]  O. Lopez,et al.  Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. , 1998, Archives of neurology.

[25]  E. Perry,et al.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.

[26]  Murat Emre,et al.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.

[27]  S. Tanada,et al.  Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. , 2002, Archives of general psychiatry.

[28]  A. Myers,et al.  Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease , 1998, Brain Research.

[29]  K. Erlandsson,et al.  Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. , 2003, The American journal of psychiatry.

[30]  J. Joyce,et al.  Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. , 1997, Archives of general psychiatry.

[31]  A. Burns,et al.  Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought Content , 1990, British Journal of Psychiatry.

[32]  J. Meador-Woodruff,et al.  Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia , 1997, Neuropsychopharmacology.

[33]  P. Hof,et al.  Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease , 2003, Acta Neuropathologica.

[34]  T. Robbins,et al.  Chemical neuromodulation of frontal-executive functions in humans and other animals , 2000, Experimental Brain Research.

[35]  E. Perry,et al.  Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia , 1990, Journal of neurochemistry.

[36]  E. Perry,et al.  Cerebral Cholinergic Activity Is Related to the Incidence of Visual Hallucinations in Senile Dementia of Lewy Body Type , 1990 .

[37]  S. Leurgans,et al.  Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients , 2006, Movement disorders : official journal of the Movement Disorder Society.

[38]  M. Laakso,et al.  Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease , 2003, The European journal of neuroscience.

[39]  J. Joyce,et al.  Loss of Dopamine D2 Receptors in Alzheimer's Disease with Parkinsonism But Not Parkinson's or Alzheimer's Disease , 1998, Neuropsychopharmacology.

[40]  Robert H. Perry,et al.  Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.

[41]  Wayne C. Drevets,et al.  Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type , 1989, Biological Psychiatry.

[42]  A. Kurz,et al.  DELUSIONS AND HALLUCINATIONS IN ALZHEIMER'S DISEASE: RESULTS FROM A TWO‐YEAR LONGITUDINAL STUDY , 1996 .

[43]  D. Blanchard,et al.  Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  R. Lévy,et al.  Psychiatric Phenomena in Alzheimer's Disease. IV: Disorders of Behaviour , 1990, British Journal of Psychiatry.

[45]  K. Neve,et al.  Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. , 1992, The Journal of pharmacology and experimental therapeutics.

[46]  Patrick R Hof,et al.  Mice Lacking Dopamine D2 and D3 Receptors Have Spatial Working Memory Deficits , 2002, The Journal of Neuroscience.

[47]  J. Moossy,et al.  Neuropathologic and neurochemical correlates of psychosis in primary dementia. , 1991, Archives of neurology.

[48]  Dag Aarsland,et al.  Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. , 2005, The Journal of clinical psychiatry.

[49]  L. Nyberg,et al.  The correlative triad among aging, dopamine, and cognition: Current status and future prospects , 2006, Neuroscience & Biobehavioral Reviews.

[50]  A. Burns,et al.  Psychiatric Phenomena in Alzheimer's Disease. III: Disorders of Mood , 1990, British Journal of Psychiatry.

[51]  E. Perry,et al.  Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.

[52]  Y. Hirayasu,et al.  Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  G. Stebbins,et al.  Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.

[54]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[55]  I. McKeith,et al.  Neuroleptic sensitivity to risperidone in Lewy body dementia , 1995, The Lancet.

[56]  E. Perry,et al.  Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease , 1998, Biological Psychiatry.

[57]  J. T. Tran,et al.  Dementia with lewy bodies: therapeutic opportunities and pitfalls. , 2006, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[58]  C. Fairburn,et al.  Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up , 1997, BMJ.

[59]  J. Trojanowski,et al.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.

[60]  E. Perry,et al.  Delusions associated with elevated muscarinic binding in dementia with Lewy bodies , 2000, Annals of neurology.

[61]  Hans Förstl,et al.  Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings , 1993, Acta psychiatrica Scandinavica.

[62]  G. Wilcock,et al.  The prevalence and phenomenology of psychotic symptoms in dementia sufferers , 1995 .

[63]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[64]  J. Copeland,et al.  Computerized diagnosis from a standardized history schedule: A preliminary communication about the organic section of the HAS–AGECAT system , 1992 .

[65]  A. Antal,et al.  Dopamine D2 receptor blockade alters the primary and cognitive components of visual evoked potentials in the monkey, Macaca fascicularis , 1997, Neuroscience Letters.

[66]  A. Burns,et al.  Psychiatric Phenomena in Alzheimer's Disease. II: Disorders of Perception , 1990, British Journal of Psychiatry.

[67]  L. Schneider,et al.  Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. , 1994, Archives of neurology.

[68]  S. Papapetropoulos,et al.  Factors associated with drug–induced visual hallucinations in Parkinson's disease , 2005, Journal of Neurology.

[69]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Wisniewski,et al.  Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. , 2001, Archives of neurology.